Helus Pharma Inc.(HELP)

Medical - Pharmaceuticals · Toronto, ON

$10.85-0.57 (-4.99%)

Delayed quote: Oct 6, 2026, 1:35 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T17:36:46.462Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:36:46.462Z.

Quote observation: 2026-10-06T17:35:07.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 672,527,485
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 166,165,362
TTM free cash flow · period ending 2026-06-30: -154,590,517.3

FMP input reference: 934548bd97ab8c390298f716fcf622fc2d1107cfab085c47b2b47650fd31fbc6

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

HELP EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

HELP Competitors' EV/FCF Ratio

HELP

Helus Pharma Inc.

Current

Market Cap

$672.53M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SLDB

Solid Biosciences Inc.

vs HELP

Market Cap

$676.84M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANNX

Annexon, Inc.

vs HELP

Market Cap

$665.18M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FDMT

4D Molecular Therapeutics, Inc.

vs HELP

Market Cap

$664.43M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDXG

MiMedx Group, Inc.

vs HELP

Market Cap

$664.67M

EV/FCF Ratio

13.07x

TTM Avg

10.66x

3Y Avg

30.61x

5Y Avg

30.61x

AVBP

ArriVent BioPharma, Inc.

vs HELP

Market Cap

$681.62M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STLN

Starling Oncology, Inc.

vs HELP

Market Cap

$656.39M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVR

Anteris Technologies Global Corp.

vs HELP

Market Cap

$694.33M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OLMA

Olema Pharmaceuticals, Inc.

vs HELP

Market Cap

$697.69M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVTX

Avalo Therapeutics, Inc.

vs HELP

Market Cap

$701.75M

EV/FCF Ratio

N/A

TTM Avg

1185.88x

3Y Avg

1179.74x

5Y Avg

1179.74x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Helus Pharma Inc. (HELP)	$672.53M	N/A	N/A	N/A	N/A
Solid Biosciences Inc. (SLDB)vs ›	$676.84M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$665.18M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$664.43M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$664.67M	13.07x	10.66x	30.61x	30.61x
ArriVent BioPharma, Inc. (AVBP)vs ›	$681.62M	N/A	N/A	N/A	N/A
Starling Oncology, Inc. (STLN)vs ›	$656.39M	N/A	N/A	N/A	N/A
Anteris Technologies Global Corp. (AVR)vs ›	$694.33M	N/A	N/A	N/A	N/A
Olema Pharmaceuticals, Inc. (OLMA)vs ›	$697.69M	N/A	N/A	N/A	N/A
Avalo Therapeutics, Inc. (AVTX)vs ›	$701.75M	N/A	1185.88x	1179.74x	1179.74x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

HELP EV/FCF Ratio Metrics

HELP Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics